Internal Medicine, Endocrinology, Diabetes, & Metabolism · Whitehall, PA
NPI
1700861630
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
3671 Crescent Ct E
Whitehall, PA, 18052
Phone (484) 664-7300
Groups this clinician bills Medicare through
Medicare paid, 2024
$21K
377 services
Medicare patients, 2024
119
Average age 69
Drug cost, 2024
$8.8M
16,234 prescriptions
Company payments, 2025
$81K
From 40 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Geraldo A Saavedra was code 99214 (office e&m - established), 180 times for 108 patients. In total Geraldo A Saavedra billed 377 services in 14 codes, and Medicare paid $21K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-09-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 180 | 108 | $84.10 | $15K |
| 82962 Clinical Chemistry | Office | 83 | 51 | $3.21 | $266 |
| 95251 Test - Miscellaneous | Office | 57 | 29 | $25.72 | $1,466 |
By year: 2022 $34K for 696 services; 2023 $33K for 635 services; 2024 $21K for 377 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 83 | 51 | $3.21 | $266 |
Medicare prescription drug claims, 2024
In 2024, the drug Geraldo A Saavedra prescribed most often to Medicare patients was Mounjaro (Tirzepatide), with 926 prescriptions and refills. In total Geraldo A Saavedra wrote 16,234 Medicare prescriptions that cost $8.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | 926 | 962 | 190 | $999K |
| Trulicity Dulaglutide | 702 | 814 | 119 | $772K |
| Atorvastatin Calcium Generic | 681 | 1,678 | 167 | $9,213 |
| Jardiance Empagliflozin | 647 | 1,402 | 160 | $812K |
| Levothyroxine Sodium Generic | 637 | 1,610 | 137 | $6,530 |
| Ozempic Semaglutide | 564 | 741 | 97 | $699K |
| Rosuvastatin Calcium Generic | 548 | 1,337 | 155 | $9,041 |
| Ezetimibe Generic | 476 | 1,197 | 137 | $12K |
| Amlodipine Besylate Generic | 436 | 1,049 | 120 | $2,795 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 429 | 885 | 120 | $35K |
| Kerendia Finerenone | 413 | 895 | 94 | $560K |
| Lisinopril Generic | 404 | 964 | 104 | $2,906 |
| Losartan Potassium Generic | 369 | 910 | 101 | $2,905 |
| Alcohol Prep Pads Alcohol Antiseptic Pads | 365 | 596 | 103 | $10K |
| Metformin Hcl Er Metformin Hcl | 298 | 738 | 89 | $4,897 |
Brand drugs: 7,086 claims; generic drugs: 7,056 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Geraldo A Saavedra $81K ($81K in general payments such as food, travel and fees) from 40 companies. The largest payer was Lilly USA, LLC with $45K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 90 | $45K |
| Novo Nordisk Inc NVO | 54 | $23K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $2,743 |
| CeQur Corporation | 3 | $1,863 |
| Medtronic, Inc. MDT | 14 | $892 |
| Madrigal Pharmaceuticals MDGL | 11 | $800 |
| Amgen Inc. AMGN | 32 | $752 |
| Xeris Pharmaceuticals, Inc. | 32 | $642 |
| AstraZeneca Pharmaceuticals LP AZN | 13 | $603 |
| Corcept Therapeutics CORT | 15 | $601 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.